ArticleAnnals of medicine2025
Adrenal vein sampling in primary aldosteronism: a retrospective analysis of clinical experience in the Middle East.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextAdrenal vein sampling (AVS) is the gold standard for lateralizing aldosterone secretion in primary aldosteronism (PA) management. However, due to challenges in expertise and infrastructure, it remains underutilized in the Middle East (ME).
objectivesThis study aimed to document the performance and outcomes of AVS in the ME.
methodsThis retrospective study included patients with PA who underwent AVS at a tertiary care hospital in Qatar (2015 - 2024). Clinical, biochemical, imaging and procedural data were collected to evaluate AVS success rates, imaging-AVS concordance and treatment outcomes. AVS success was defined as correct bilateral adrenal vein cannulation, determined by selectivity indices (unstimulated SI ≥ 2 or cosyntropin-stimulated SI ≥ 5).
resultsThe cohort (
conclusionThis study is the first to demonstrate AVS's safety and efficacy in the ME, achieving a 71% success rate. With an AVS-imaging concordance of only 59%, the study highlights the clinical significance of AVS in guiding optimal management decisions. AVS-directed interventions lead to better treatment strategies with high post-treatment cure rates. The role of technology, such as intraprocedural dynaCT, is reinforced in improving procedural accuracy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.